Evidence map›Paper›PMID 41144061›Full record

ArticleJournal of neuro-oncology2025

Clinical and survival differences between thalamic glioblastoma and thalamic diffuse midline glioma, H3 K27-altered.

Peigang Ji, Chen Li, Yuan Wang, Shaochun Guo, Yulong Zhai, Na Wang, Jinghui Liu, Liang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peigang Ji *Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Chen Li *Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Yuan WangDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Shaochun GuoDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Yulong ZhaiDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Na WangDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Jinghui LiuDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China. doctorliujinghui@126.com.
Liang WangDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China. Drwangliang@126.com.

Funding

The Science Fund for Distinguished Young Scholars of Shaanxi Province No. 2023-JC-JQ-68Youth Innovation Team of Shaanxi Provincial Higher Education Institutions 2022-61
6 · The paper itself

Abstract

purposeThe 2021 WHO classification describes a specific subgroup of diffuse midline glioma, H3 K27-altered (DMG-H3 K27-altered), which arises in the thalamus or other midline structures. To date, the prognosis of thalamic DMG-H3 K27-altered remains controversial, and no studies have compared its overall survival (OS) with that of glioblastoma (GBM). The present study aimed to compare the clinical features and survival outcomes of patients with thalamic DMG-H3 K27-altered and those with thalamic GBM.

methodsThis was a retrospective, single-center study. The clinical characteristics, pathological findings, treatment modalities, and prognostic outcomes of the patients were summarized. Survival analyses were conducted using the Kaplan-Meier and Cox regression analyses.

resultsWe screened 44 patients diagnosed with thalamic GBM, and 43 with thalamic DMG-H3 K27-altered. Compared with GBM, patients with DMG-H3 K27-altered were significantly younger (median age: 40 vs. 49 years, p = 0.039), exhibited lower Ki67 index, and had less MGMT promoter methylation rates. The median OS was significantly prolonged in thalamic DMG-H3 K27-altered compared with GBM among patients treated according to the Stupp protocol (26.3 vs. 14.7 months, p = 0.019). In patients with thalamic DMG-H3 K27-altered group, slight or no enhancement on magnetic resonance imaging (MRI) was significantly associated with prolonged OS (26.3 vs. 13.7 months, p = 0.031).

conclusionsThe OS of thalamic DMG-H3 K27-altered was superior to GBM among patients who received treatment according to the Stupp-protocol. Slight or no enhancement on MRI was significantly associated with prolonged OS in patients with thalamic DMG-H3 K27-altered.

Indexed as

Brain NeoplasmsGlioblastomaGliomaHistonesThalamusAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateYoung AdultHistonesDiffuse midline gliomaGlioblastomaMagnetic resonance imagingOverall survivalThalamus

Identifiers

PMID41144061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.